PDT Partners’s Apollo Endosurgery, Inc. APEN Stock Holding History

PDT Partners’s Portfolio APEN Stock Details APEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-14,717	Closed	-$89K	–	1213
2022 Q1	$89K	Buy	+14,717	New	+$89.7K	0.01%	874

Other funds holding APEN

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Gagnon Advisors New York $136M AUM 21.55% 1-Year Est. Return

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

PDT Partners's APEN Position: Q2 2022 in Review

PDT Partners sold out of Apollo Endosurgery, Inc. (APEN) in Q2 2022, closing a stake of 14,717 shares — an estimated $89K sold.

PDT Partners first reported a position in APEN in Q1 2022 and held it in 1 quarter. The position peaked at $89K in Q1 2022. 63 funds tracked by Wall St. Rank hold APEN as of Q2 2022.

PDT Partners reported no remaining Apollo Endosurgery, Inc. position as of Q2 2022 after selling out during the quarter.
PDT Partners sold 14,717 Apollo Endosurgery, Inc. shares in Q2 2022, an estimated $89K.
PDT Partners first reported a position in Apollo Endosurgery, Inc. in Q1 2022 and held it in 1 quarter.
PDT Partners's Apollo Endosurgery, Inc. position peaked at $89K in Q1 2022.
63 funds tracked by Wall St. Rank held Apollo Endosurgery, Inc. as of Q2 2022.

Based on PDT Partners's 13F filing for Q2 2022, filed 15 Aug 2022.